Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Karyopharm Therapeutics (NASDAQ: KPTI) after the company announced lead ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE